Malco, Ceat, Cummins & Dishman Pharma results

CORPORATE SCORECARD

Malco net drops 26% to Rs 8.6 cr

Madras Aluminium Company (Malco) recorded a net profit of Rs 8.60 crore in the third quarter of 2004-05, lower by 25.86 per cent compared with Rs 11.60 crore in the corresponding period of the previous year.

Net sales during the quarter stood at Rs 75.28 crore, higher by 9.1 per cent compared with the year-ago period's Rs 69.01 crore.

The company's press release said the fall in net profit was mainly on account of higher deferred tax provision of Rs 2.90 crore in the third quarter as against a credit of Rs 2.10 crore last year.

Ceat net drops 19% to Rs 1.14 cr

Ceat has posted a 19 per cent dip in its net profit for the third quarter ended December 31, 2004 to Rs 1.14 crore. The company's net sales in the third quarter grew 10 per cent to Rs 379.98 crore from Rs 344.29 crore in the same quarter of 2003.

Operating profit dipped 13 per cent from Rs 25.20 crore to Rs 21.78 crore in the December 2004 quarter. The company posted a 20 per cent growth in its exports in the quarter.

Cummins net up by 22% to Rs 32.85 cr

Cummins India reported a 22 per cent increase in its net profit at Rs 32.85 crore for the quarter ended December 31, 2004 compared with rs 26.94 crore during the corresponding period previous year.

Total income increased by 32 per cent to Rs 324.01 crore for the quarter against Rs 245.44 crore in in the year-ago period, Cummins informed the bombay stock exchange.

The company has also announced payment of 100 per cent interim dividend for 2004-2005 on 198,000,000 equity shares of Rs 2 each. The record date for payment of interim dividend has been fixed as February 14, 2005.

Dishman Pharma net up 133% to Rs 8.78 cr

The Ahmedabad-based Dishman Pharmaceuticals and Chemicals has reported a 133 per cent rise in its net profit for the quarter ending December 31, 2004 to Rs 8.78 crore compared with Rs 3.77 crore for the corresponding period last year.

Total income for the third quarter ending December 31, 2004 stood at Rs 44.25 crore compared with Rs 33.42 crore for the corresponding period int he previous year.

During the quarter, the contribution to sales by marketable molecules was 60 per cent, while contract manufacturing and research accounted for 40 per cent.

For the corresponding quarter last year, the contribution of marketable molecules to sales was 80 per cent, while contract manufacturing and research accounted for the remaining 20 per cent.